Cargando…

Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

OBJECTIVE: Post-hoc analysis to compare the outcomes of brolucizumab 6 mg vs. aflibercept 2 mg in neovascular age-related macular degeneration (nAMD) patients with early persistent retinal fluid in HAWK and HARRIER. METHODS: After 3 monthly loading doses, brolucizumab-treated eyes (N = 730) received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lally, David R., Loewenstein, Anat, Arnold, Jennifer J., Yang, Yit C., Gedif, Kinfemichael, Best, Catherine, Patel, Hersh, Tadayoni, Ramin, Heier, Jeffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102125/ https://www.ncbi.nlm.nih.gov/pubmed/35597816 http://dx.doi.org/10.1038/s41433-022-02092-5

Ejemplares similares

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies
por: Lally, David R., et al.
Publicado: (2022)

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
por: Tadayoni, Ramin, et al.
Publicado: (2023)

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
por: Ogura, Yuichiro, et al.
Publicado: (2022)

Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020)

Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis
por: Schmidt-Erfurth, Ursula, et al.
Publicado: (2022)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
por: Mukai, Ryo, et al.
Publicado: (2022)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies
por: Eichenbaum, David, et al.
Publicado: (2023)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Complete mitochondrial genomesequence of the hen harrier (Circus cyaneus)
por: Gao, Xiaodong, et al.
Publicado: (2018)

Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model
por: Schubert, William, et al.
Publicado: (2022)

Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits
por: Ramon, Dan, et al.
Publicado: (2018)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup
por: Okada, Annabelle A., et al.
Publicado: (2022)

GPS tracking data of Western marsh harriers breeding in Belgium and the Netherlands
por: Milotić, Tanja, et al.
Publicado: (2020)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
por: Mishra, Sanjay Kumar, et al.
Publicado: (2022)

Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Kato, Nobuhiro, et al.
Publicado: (2023)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Angermann, Reinhard, et al.
Publicado: (2022)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Brolucizumab for macular degeneration
Publicado: (2020)

Side Effects of Brolucizumab
por: Motevasseli, Tahmineh, et al.
Publicado: (2021)

The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
por: Pearce, Ian, et al.
Publicado: (2022)

Nests of Marsh harrier (Circus aeruginosus L.) as refuges of potentially phytopathogenic and zoopathogenic fungi
por: Kornillowicz-Kowalska, Teresa, et al.
Publicado: (2018)

Female begging calls reflect nutritional need of nestlings in the hen harrier Circus cyaneus
por: Redpath, Steve, et al.
Publicado: (2017)

The Influence of Biological Factors on Haematological Values in Wild Marsh Harrier (Circus aeruginosus) Nestlings
por: Zaremba, Urszula, et al.
Publicado: (2021)

Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema
por: Korobelnik, Jean-François, et al.
Publicado: (2022)

Erratum: Side Effects of Brolucizumab
Publicado: (2022)

Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
por: Sydnor, Shelby, et al.
Publicado: (2023)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations
por: Yang, Yit, et al.
Publicado: (2015)

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
por: Khoramnia, Ramin, et al.
Publicado: (2021)

Is This a 737 Max Moment for Brolucizumab?
por: Rosenfeld, Philip J., et al.
Publicado: (2020)

Hawking Incorporated: Stephen Hawking and the Anthropology of the Knowing Subject
por: Mialet, Hélène
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_su2joced45lsnuhfrtkvg0eifg